Initiate Ventures

www.initiate.vc

VCMatch tracks Initiate Ventures as an investor focused on AI/ML, Pharma, and Enterprise SaaS companies, Pre-Seed and Seed rounds, United States markets, and $500k to $2m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$500k to $2m

Stages

Pre-Seed, Seed, Series A

Focus Areas

AI/ML, Pharma, Enterprise SaaS

Geography

United States

Investment Thesis

INITIATE positions itself as a hands-on, founder-focused venture firm that combines operator and investor experience to accelerate early-stage companies in healthcare, tech, and life sciences. They emphasize partnering beyond capital—providing mentorship, strategic introductions, and operational support (milestone development, talent acquisition, fundraising) via a Studio that can act as an “experienced co-founder”—with a goal of helping founders “get farther faster” while raising capital strategically with less dilution and maintaining more control.

Is Initiate Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Initiate Ventures is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in AI/ML, Pharma, Enterprise SaaS, and Digital Health, especially across United States, with public check-size signals around $500k to $2m.

Focus statement

INITIATE focuses on early-stage (Pre-Seed to Series A) US-based companies in health tech and life sciences — specifically AI-driven biopharma tech & services, precision medicine, life sciences SaaS and tools, and novel care delivery and payment models — making initial investments of $500K–$2M and reserving follow-on capital. They explicitly state they "don’t invest in pure biotech, medical devices, or agtech."

Value Add

Studio model that "partners with entrepreneurs to co-create and launch new companies" and can act as an "experienced co-founder" providing operational and strategic support.
Founding team of former operators and investors with direct exits and scale experience (examples cited: GRAIL, Invitae, Genomic Health)—bringing clinical, commercial, and fundraising know-how.
Emphasis on hands-on mentorship, strategic introductions and network effects as core to value-add: "We’re an extension of your team and can strategically lighten the load."
Clear stage and ticket-size transparency (Pre-Seed to Series A; $500K–$2M initial checks) and flexibility to lead, co-lead, or syndicate.
Strategic aim to help founders raise capital with "less dilution" and to maintain more control — signaling operational involvement that prioritizes founder outcomes.
Targeted sector focus (health tech/life sciences subsegments) with explicit exclusions (no pure biotech, medical devices, agtech), which clarifies domain expertise and investment boundaries.